Seeking Alpha

Selecta Bio completes enrollment in SEL-212 study; shares up 23% premarket

|About: Selecta Biosciences, Inc. (SELB)|By: , SA News Editor

Thinly traded nano cap Selecta Biosciences (NASDAQ:SELB) is up 23% premarket on increased volume in response to the completion of enrollment in a 150-subject Phase 2 clinical trial, COMPARE, evaluating lead candidate SEL-212 (ImmTOR + pegadricase) versus a bi-weekly dose of pegloticase [Horizon Therapeutics' (NASDAQ:HZNP) Krystexxa] in patients with chronic treatment-resistant gout.

The primary endpoint is the maintenance of serum uric acid levels below 6 mg/dL (normal ranges for women and men: 2.4-6.0 mg/dL and 3.4-7.0 mg/dL, respectively) at months 3 & 6. Topline data should be available by mid-2020.

Try Seeking Alpha PREMIUM for unlimited analysis on SELB